Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | RXRA | P19793 | 2/20 | 0.57 |
| ▸ | RXRB | P28702 | 2/20 | 0.57 |
| ▸ | RXRG | P48443 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4745951 | 0.88 | FFAR1 (0.60) | RXRARXRBRXRGADRB3 | |
| SCHEMBL13802457 | 0.87 | MRGPRX4 (0.63) | HIF1AMRGPRX4HDAC6HDAC8 | |
| SCHEMBL6840198 | 0.85 | PPARA (0.60) | RXRARXRBRXRGMRGPRX4POLB | |
| SCHEMBL29080372 | 0.84 | PTK2 (0.59) | HIF1AHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL30519428 | 0.84 | PTK2 (0.59) | HIF1AHDAC1HDAC6HDAC3HDAC2 | |
| SCHEMBL30687018 | 0.84 | FFAR1 (0.65) | ADRB2ADRB1ADRB3HDAC4MEF2D | |
| SCHEMBL30687014 | 0.84 | FFAR1 (0.65) | ADRB2ADRB1ADRB3HDAC4MEF2D | |
| SCHEMBL29129870 | 0.84 | FFAR1 (0.65) | ADRB2ADRB1ADRB3HDAC4MEF2D | |
| SCHEMBL4748420 | 0.83 | HIF1A (0.68) | HIF1AMRGPRX4HDAC6HDAC8POLB | |
| SCHEMBL27487037 | 0.83 | HIF1A (0.69) | HIF1AMRGPRX4HDAC6HDAC8POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-4362892-A | ARALKYLANILINES, ANTICHOLESTEROL AGENTS | BEECHAM GROUP LIMITED (GB) | 1982-12-07 | — | — | US | disclosed |
| US-4207330-A | Method for treating hyperglycemia in mammals using arylamino benzoic acids | THE DOW CHEMICAL COMPANY (US) | 1980-06-10 | — | — | US | disclosed |
| US-4206145-A | ALKANOYL-SUBSTITUTED ARALKYLAMINES | BEECHAM GROUP LIMITED (GB) | 1980-06-03 | — | — | US | disclosed |
| US-4143151-A | METHOD FOR TREATING HYPERGLYCEMIA IN MAMMALS USING ARYLAMINO BENZOIC ACIDS | THE DOW CHEMICAL COMPANY (US) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | HIF1A 2788/4885RXRA 3288/4885RXRB 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.